C
Charles M. Perou
Researcher at University of North Carolina at Chapel Hill
Publications - 645
Citations - 235604
Charles M. Perou is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 156, co-authored 573 publications receiving 202951 citations. Previous affiliations of Charles M. Perou include North Carolina Central University & University of Chicago.
Papers
More filters
Journal ArticleDOI
Estrogen and progesterone receptor testing in breast cancer: American society of clinical oncology/college of American pathologists guideline update
Kimberly H. Allison,M. Elizabeth H. Hammond,Mitchell Dowsett,Shannon E. McKernin,Lisa A. Carey,Patrick L. Fitzgibbons,Daniel F. Hayes,Sunil R. Lakhani,Mariana Chavez-MacGregor,Jane Perlmutter,Charles M. Perou,Meredith M. Regan,David L. Rimm,W. Fraser Symmans,Emina Torlakovic,Emina Torlakovic,Leticia Varella,Giuseppe Viale,Giuseppe Viale,Tracey Weisberg,Lisa M. McShane,Antonio C. Wolff +21 more
TL;DR: The Expert Panel continues to recommend ER testing of invasive breast cancers by validated immunohistochemistry as the standard for predicting which patients may benefit from endocrine therapy, and no other assays are recommended for this purpose.
Journal ArticleDOI
Molecular Features and Survival Outcomes of the Intrinsic Subtypes Within HER2-Positive Breast Cancer
Aleix Prat,Lisa A. Carey,Barbara Adamo,Maria Vidal,Josep Tabernero,Javier Cortes,Joel S. Parker,Charles M. Perou,José Baselga +8 more
TL;DR: When the intrinsic subtypes are taken into account, cHER2-positivity does not translate into large changes in the expression of downstream signaling pathways, nor does it affect patient survival in the absence of HER2 targeting.
Journal ArticleDOI
RNA expression analysis of formalin-fixed paraffin-embedded tumors.
Shannon K. Penland,Temitope O. Keku,Chad Torrice,Xiaping He,Janakiraman Krishnamurthy,Katherine A. Hoadley,John T. Woosley,Nancy E. Thomas,Charles M. Perou,Robert S. Sandler,Norman E. Sharpless +10 more
TL;DR: It is shown that informative RNA expression analysis can be derived from selected FFPE samples, and unsupervised analysis of informative gene expression profiles distinguished tumor type and subtype, and identified tumor tissue of origin in three unclassified carcinomas.
Journal ArticleDOI
RERG Is a Novel ras-related, Estrogen-regulated and Growth-inhibitory Gene in Breast Cancer *
Brian S. Finlin,Chia Ling Gau,Gretchen A. Murphy,Haipeng Shao,Tracy Kimel,Robert S. Seitz,Yen Feng Chiu,David Botstein,Patrick O. Brown,Channing J. Der,Fuyuhiko Tamanoi,Douglas A. Andres,Charles M. Perou +12 more
TL;DR: This paper identified a unique ras superfamily gene, termed RERG (ras-related and estrogen-regulated growth inhibitor), whose expression was decreased or lost in a significant percentage of primary human breast tumors that show a poor clinical prognosis.
Journal ArticleDOI
TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer
Lisa A. Carey,Hope S. Rugo,Paul K. Marcom,William J. Irvin,Madlyn Ferraro,E. Burrows,Xiaping He,Charles M. Perou,EP Winer +8 more
TL;DR: TBCRC 001 is a multicenter randomized phase II study of cetuximab alone and combined with carboplatin (P) in TN metastatic BrCa and primary endpoint was objective response (RR, CR+PR).